Jazz Pharmaceuticals, Inc. drugs
8 results
Defitelio (defibrotide sodium)
(defibrotide sodium)Jazz Pharmaceuticals, Inc.
Usage: DEFITELIO is indicated for treating hepatic veno-occlusive disease (VOD), or sinusoidal obstruction syndrome (SOS), in adult and pediatric patients with renal or pulmonary dysfunction after hematopoietic stem-cell transplantation (HSCT).
Epidiolex (cannabidiol)
(cannabidiol)Jazz Pharmaceuticals, Inc.
Usage: EPIDIOLEX is indicated for treating seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), and tuberous sclerosis complex (TSC) in patients aged 1 year and older.
Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn)
(asparaginase erwinia chrysanthemi (recombinant)-rywn)Jazz Pharmaceuticals, Inc.
Usage: RYLAZE is indicated for use in combination with other chemotherapy agents to treat acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) in adults and pediatric patients aged 1 month and older who are hypersensitive to E. coli-derived asparaginase.
Vyxeos ((daunorubicin and cytarabine) liposome)
((daunorubicin and cytarabine) liposome)Jazz Pharmaceuticals, Inc.
Usage: VYXEOS is indicated for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) and acute myeloid leukemia with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients aged 1 year and older.
Xyrem (sodium oxybate)
(sodium oxybate)Jazz Pharmaceuticals, Inc.
Usage: Xyrem is indicated for treating cataplexy and excessive daytime sleepiness (EDS) in patients aged 7 and older with narcolepsy.
Xywav (calcium, magnesium, potassium, and sodium oxybates)
(calcium, magnesium, potassium, and sodium oxybates)Jazz Pharmaceuticals, Inc.
Usage: XYWAV is indicated for treating cataplexy and excessive daytime sleepiness in patients aged 7 and older with narcolepsy, as well as for the treatment of idiopathic hypersomnia in adults.
Zepzelca (lurbinectedin)
(Lurbinectedin)Jazz Pharmaceuticals, Inc.
Usage: ZEPZELCA is indicated for treating adult patients with metastatic small cell lung cancer (SCLC) who have disease progression after platinum-based chemotherapy. This approval is under accelerated conditions, contingent on further confirmation of clinical benefit in ongoing trials.
Ziihera (zanidatamab-hrii)
(zanidatamab-hrii)Jazz Pharmaceuticals, Inc.
Usage: ZIIHERA is indicated for treating adults with unresectable or metastatic HER2-positive biliary tract cancer (BTC) that has been previously treated, as determined by an FDA-approved test. This indication is based on accelerated approval due to overall response rate and duration of response.